87 related articles for article (PubMed ID: 8765669)
1. Synthesis and receptor binding affinity of cholecystokinin receptor ligands: 2-and 1-indolyl derivatives of PD134308.
Araldi G; Donati D; Oliosi B; Ursini A; van Amsterdam F; Natalini B; Pellicciari R; Tarzia G
Farmaco; 1996 Jul; 51(7):471-6. PubMed ID: 8765669
[TBL] [Abstract][Full Text] [Related]
2. 'Targeted' molecular diversity: design and development of non-peptide antagonists for cholecystokinin and tachykinin receptors.
Horwell D; Pritchard M; Raphy J; Ratcliffe G
Immunopharmacology; 1996 Jun; 33(1-3):68-72. PubMed ID: 8856117
[TBL] [Abstract][Full Text] [Related]
3. Development of CCK-B antagonists.
Horwell DC
Neuropeptides; 1991 Jul; 19 Suppl():57-64. PubMed ID: 1881533
[TBL] [Abstract][Full Text] [Related]
4. Conformationally restricted analogues of the potent CCK-B antagonist CI-988.
Higginbottom M; Hill DR; Horwell DC; Mostafai E; Suman-Chauhan N; Roberts E
Bioorg Med Chem; 1993 Sep; 1(3):209-17. PubMed ID: 8081854
[TBL] [Abstract][Full Text] [Related]
5. Cholecystokinin B antagonists. Synthesis and quantitative structure-activity relationships of a series of C-terminal analogues of CI-988.
Augelli-Szafran CE; Horwell DC; Kneen C; Ortwine DF; Pritchard MC; Purchase TS; Roth BD; Trivedi BK; Hill D; Suman-Chauhan N; Webdale L
Bioorg Med Chem; 1996 Oct; 4(10):1733-45. PubMed ID: 8931944
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin-A receptor antagonist.
Fukamizu Y; Nakajima T; Kimura K; Kanda H; Fujii M; Saito T; Kasai H
Arzneimittelforschung; 1998 Jan; 48(1):58-64. PubMed ID: 9522034
[TBL] [Abstract][Full Text] [Related]
7. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity.
Hughes J; Boden P; Costall B; Domeney A; Kelly E; Horwell DC; Hunter JC; Pinnock RD; Woodruff GN
Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6728-32. PubMed ID: 1975695
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological properties of new constrained CCK-B antagonists: discrimination of two affinity states of the CCK-B receptor on transfected CHO cells.
Bellier B; McCort-Tranchepain I; Ducos B; Danascimento S; Meudal H; Noble F; Garbay C; Roques BP
J Med Chem; 1997 Nov; 40(24):3947-56. PubMed ID: 9397175
[TBL] [Abstract][Full Text] [Related]
9. Suppression of conditioned fear by administration of CCKB receptor antagonist PD135158.
Tsutsumi T; Akiyoshi J; Isogawa K; Kohno Y; Hikichi T; Nagayama H
Neuropeptides; 1999 Dec; 33(6):483-6. PubMed ID: 10657528
[TBL] [Abstract][Full Text] [Related]
10. Antinociceptive effects of RB101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a cholecystokinin type B receptor antagonist, as revealed by noxiously evoked spinal c-Fos expression in rats.
Honore P; Buritova J; Fournié-Zaluski MC; Roques BP; Besson JM
J Pharmacol Exp Ther; 1997 Apr; 281(1):208-17. PubMed ID: 9103499
[TBL] [Abstract][Full Text] [Related]
11. PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes.
Wiesenfeld-Hallin Z; Xu XJ; Hughes J; Horwell DC; Hökfelt T
Proc Natl Acad Sci U S A; 1990 Sep; 87(18):7105-9. PubMed ID: 1698290
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists).
de Tullio P; Delarge J; Pirotte B
Curr Med Chem; 1999 Jun; 6(6):433-55. PubMed ID: 10213792
[TBL] [Abstract][Full Text] [Related]
13. [Cholecystokinin receptor antagonists].
Ohtsuka T; Yokose K
Tanpakushitsu Kakusan Koso; 1993 Aug; 38(11):1853-62. PubMed ID: 8210429
[No Abstract] [Full Text] [Related]
14. CI-988 inhibits growth of small cell lung cancer cells.
Moody TW; Jensen RT
J Pharmacol Exp Ther; 2001 Dec; 299(3):1154-60. PubMed ID: 11714907
[TBL] [Abstract][Full Text] [Related]
15. Anxiolytic effects of CCK-B antagonists.
Costall B; Domeney AM; Hughes J; Kelly ME; Naylor RJ; Woodruff GN
Neuropeptides; 1991 Jul; 19 Suppl():65-73. PubMed ID: 1679211
[TBL] [Abstract][Full Text] [Related]
16. Localization of CCK-1R in the omasum and role of CCK in the regulation of omasal contractions in sheep.
Onaga T; Sugita A; Wakaiki R; Hara I; Kagawa K; Kirisawa R; Hayashi H
Domest Anim Endocrinol; 2008 Aug; 35(2):231-44. PubMed ID: 18638666
[TBL] [Abstract][Full Text] [Related]
17. Studies on the effect of systemic PD134308 (CAM 958) in spinal reflex and pain models with special reference to interaction with morphine and intrathecal galanin.
Wiesenfeld-Hallin Z; Xu XJ; Hughes J; Horwell DC; Hökfelt T
Neuropeptides; 1991 Jul; 19 Suppl():79-84. PubMed ID: 1715529
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecystokinin-A receptor antagonists.
Martín-Martínez M; Bartolomé-Nebreda JM; Gómez-Monterrey I; González-Muñiz R; García-López MT; Ballaz S; Barber A; Fortuño A; Del Río J; Herranz R
J Med Chem; 1997 Oct; 40(21):3402-7. PubMed ID: 9341915
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of biologic gastrin activity of compound CI-988 in the isolated, vascularly perfused rat stomach.
Marvik R; Sandvik AK; Waldum HL
Scand J Gastroenterol; 1997 Jun; 32(6):519-22. PubMed ID: 9200280
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of pentagastrin-induced pressor response in conscious rats by the CCK-B receptor antagonist CI-988 and chlordiazepoxide.
Webb JK; Rupniak NM; Boyce S
Regul Pept; 1996 Jan; 61(1):71-6. PubMed ID: 8701030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
